A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT

被引：0

作者：

Jingtao Gao

Mengqiu Gao

Jian Du

Yu Pang

Gary Mao

Nacer Lounis

Nyasha Bakare

Yanxin Jiang

Ying Zhan

Yuhong Liu

Liang Li

机构：

[1] Beijing Chest Hospital,Clinical Center On TB

[2] Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute,Department of Tuberculosis

[3] Beijing Chest Hospital,Department of Bacteriology and Immunology

[4] Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute,undefined

[5] Beijing Chest Hospital,undefined

[6] Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute,undefined

[7] Janssen Global Public Health,undefined

[8] Janssen Research & Development,undefined

[9] Janssen Pharmaceutica,undefined

[10] Janssen China Research & Development,undefined

[11] Innovation Alliance On Tuberculosis Diagnosis and Treatment (Beijing) [IATB],undefined

来源：

Trials | / 25卷

关键词：

Tuberculosis; Bedaquiline; China; Oral Short-course regimen;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 30 条

[21] Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial
L. Guglielmetti
E. Ardizzoni
M. Atger
E. Baudin
E. Berikova
M. Bonnet
E. Chang
S. Cloez
J. M. Coit
V. Cox
B. C. de Jong
C. Delifer
J. M. Do
D. Dos Santos Tozzi
V. Ducher
G. Ferlazzo
M. Gouillou
A. Khan
U. Khan
N. Lachenal
A. N. LaHood
L. Lecca
M. Mazmanian
H. McIlleron
M. Moschioni
K. O’Brien
O. Okunbor
L. Oyewusi
S. Panda
S. B. Patil
P. P. J. Phillips
L. Pichon
P. Rupasinghe
M. L. Rich
N. Saluhuddin
K. J. Seung
M. Tamirat
L. Trippa
M. Cellamare
G. E. Velásquez
S. Wasserman
P. J. Zimetbaum
F. Varaine
C. D. Mitnick
Trials, 22
[22] Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial
Patil, S. B.
Tamirat, M.
Khazhidinov, K.
Ardizzoni, E.
Atger, M.
Austin, A.
Baudin, E.
Bekhit, M.
Bektasov, S.
Berikova, E.
Bonnet, M.
Caboclo, R.
Chaudhry, M.
Chavan, V.
Cloez, S.
Coit, J.
Coutisson, S.
Dakenova, Z.
De Jong, B. C.
Delifer, C.
Demaisons, S.
Do, J. M.
Dos Santos Tozzi, D.
Ducher, V.
Ferlazzo, G.
Gouillou, M.
Khan, U.
Kunda, M.
Lachenal, N.
LaHood, A. N.
Lecca, L.
Mazmanian, M.
McIlleron, H.
Moreau, M.
Moschioni, M.
Nahid, P.
Osso, E.
Oyewusi, L.
Panda, S.
Paquet, A.
Thuong Huu, P.
Pichon, L.
Rich, M. L.
Rupasinghe, P.
Salahuddin, N.
Sanchez Garavito, E.
Seung, K. J.
Velasquez, G. E.
Vallet, M.
Varaine, F.
TRIALS, 2023, 24 (01)
[23] Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial
S. B. Patil
M. Tamirat
K. Khazhidinov
E. Ardizzoni
M. Atger
A. Austin
E. Baudin
M. Bekhit
S. Bektasov
E. Berikova
M. Bonnet
R. Caboclo
M. Chaudhry
V. Chavan
S. Cloez
J. Coit
S. Coutisson
Z. Dakenova
B. C. De Jong
C. Delifer
S. Demaisons
J. M. Do
D. Dos Santos Tozzi
V. Ducher
G. Ferlazzo
M. Gouillou
U. Khan
M. Kunda
N. Lachenal
A. N. LaHood
L. Lecca
M. Mazmanian
H. McIlleron
M. Moreau
M. Moschioni
P. Nahid
E. Osso
L. Oyewusi
S. Panda
A. Pâquet
P. Thuong Huu
L. Pichon
M. L. Rich
P. Rupasinghe
N. Salahuddin
E. Sanchez Garavito
K. J. Seung
G. E. Velásquez
M. Vallet
F. Varaine
Trials, 24
[24] The Safety and Efficacy of Prolonged Use of Bedaquiline for the Treatment of Patients with Pulmonary Multi-Drug Resistant/Rifampin-Resistant Tuberculosis: A Prospective, Cohort Study in China
Ke, Hui
Gui, Xuwei
Sun, Wenwen
Zhang, Shaojun
Yang, Yan
Zhang, Zhemin
Fan, Lin
INFECTION AND DRUG RESISTANCE, 2023, 16 : 5055 - 5064
[25] Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial
Van Rie, Annelies
De Vos, Elise
Costa, Emilyn
Verboven, Lennert
Ndebele, Felex
Heupink, Tim H.
Abrams, Steven
Fanampe, Boitumelo
Van Dyk, Anneke Van der Spoel
Charalambous, Salome
Churchyard, Gavin
Warren, Rob
TRIALS, 2022, 23 (01)
[26] Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial
Annelies Van Rie
Elise De Vos
Emilyn Costa
Lennert Verboven
Felex Ndebele
Tim H. Heupink
Steven Abrams
Boitumelo Fanampe
Anneke Van der Spoel Van Dyk
Salome Charalambous
Gavin Churchyard
Rob Warren
Trials, 23
[27] Treatment outcomes among tuberculosis patients in Jeddah, Saudi Arabia: Results of a community mobile outreach directly observed Treatment, Short-course (DOTS) project, compared to a standard facility-based DOTS: A randomized controlled trial
Al-Sahafi, Abdullah
Al-Sayali, Mashal M.
Mandoura, Najlaa
Shah, Hassan B. U.
Al Sharif, Khalid
Almohammadi, Emad L.
Abdul-Rashid, Ola A.
Assiri, Muhammad
Buksh, Mohammed F.
Alali, Mahmoud M.
Al-Garni, Abdullah
Al-Garni, Fatima
Al-Zahrani, Abdullah
Khalawi, Alaa
Alawi, Maha
Moawwad, Abdulhamed L.
Almalki, Abdulrahim I. A.
Al-Osaimi, Maataug M.
JOURNAL OF CLINICAL TUBERCULOSIS AND OTHER MYCOBACTERIAL DISEASES, 2021, 22
[28] Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial
Myungsun Lee
Jeongha Mok
Deog Kyeom Kim
Tae Sun Shim
Won-Jung Koh
Doosoo Jeon
Taehoon Lee
Seung Heon Lee
Ju Sang Kim
Jae Seuk Park
Ji Yeon Lee
Song Yee Kim
Jae Ho Lee
Kyung-Wook Jo
Byung Woo Jhun
Young Ae Kang
Joong Hyun Ahn
Chang-Ki Kim
Soyoun Shin
Taeksun Song
Sung Jae Shin
Young Ran Kim
Heejung Ahn
Seokyung Hahn
Ho Jeong Won
Ji Yeon Jang
Sang Nae Cho
Jae-Joon Yim
Trials, 20
[29] Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial
Lee, Myungsun
Mok, Jeongha
Kim, Deog Kyeom
Shim, Tae Sun
Koh, Won-Jung
Jeon, Doosoo
Lee, Taehoon
Lee, Seung Heon
Kim, Ju Sang
Park, Jae Seuk
Lee, Ji Yeon
Kim, Song Yee
Lee, Jae Ho
Jo, Kyung-Wook
Jhun, Byung Woo
Kang, Young Ae
Ahn, Joong Hyun
Kim, Chang-Ki
Shin, Soyoun
Song, Taeksun
Shin, Sung Jae
Kim, Young Ran
Ahn, Heejung
Hahn, Seokyung
Won, Ho Jeong
Jang, Ji Yeon
Cho, Sang Nae
Yim, Jae-Joon
TRIALS, 2019, 20 (1)
[30] INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial
Naidoo, Anushka
Dooley, Kelly E.
Naidoo, Kogieleum
Padayatchi, Nesri
Yende-Zuma, Nonhlanhla
Perumal, Rubeshan
Dorse, Gillian
Boodhram, Resha
Osuala, Emmanuella Chinonso
BMJ OPEN, 2022, 12 (11):

← 1 2 3 →